Targeting the indoleamine 2,3-dioxygenase pathway in cancer

Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of...

Full description

Saved in:
Bibliographic Details
Published inJournal for Immunotherapy of Cancer Vol. 3; no. 1; p. 51
Main Authors Moon, Yong Wha, Hajjar, Joud, Hwu, Patrick, Naing, Aung
Format Journal Article Book Review
LanguageEnglish
Published England BioMed Central Ltd 15.12.2015
BMJ Publishing Group LTD
BioMed Central
Subjects
Analysis
Antigens
Autoimmune diseases
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
Enzymes
Gene expression
Immune response
Immune system
Immunotherapy
Kinases
Leukemia
Lung cancer
Lymphatic system
Lymphocytes
Medical prognosis
Melanoma
Ovarian cancer
Proteins
Review
Tumors
IDO inhibitors
Indoleamine 2,3-dioxygenase
Immune surveillance
Malignancy
Immunomodulatory
Online AccessGet full text

Cover

More Information
Summary:Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-015-0094-9